We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zonisamide for Heavy Drinkers With Bipolar Disorder (ZNSBP)

This study has been terminated.
(recruitment infeasible)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01566370
First Posted: March 29, 2012
Last Update Posted: January 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Yale University
Results First Submitted: March 22, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Alcohol Use Disorders
Bipolar Disorder
Interventions: Drug: Zonisamide
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Zonisamide

Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind

Zonisamide: titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose

Placebo

Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group

Placebo: placebo


Participant Flow:   Overall Study
    Zonisamide   Placebo
STARTED   2   1 
COMPLETED   0   0 
NOT COMPLETED   2   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Heavy drinkers with bipolar disorder

Reporting Groups
  Description
Zonisamide

Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind

Zonisamide: titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose

Placebo

Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group

Placebo: placebo

Total Total of all reporting groups

Baseline Measures
   Zonisamide   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   1   3 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      2 100.0%      1 100.0%      3 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Full Range)
 58.5 
 (57 to 60) 
 45 
 (45 to 45) 
 51.75 
 (45 to 60) 
Gender 
[Units: Participants]
Count of Participants
     
Female      0   0.0%      1 100.0%      1  33.3% 
Male      2 100.0%      0   0.0%      2  66.7% 
Region of Enrollment 
[Units: Participants]
     
United States   2   1   3 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Total Heavy Drinking Days   [ Time Frame: from week 11 through 14 (over 4 weeks) ]

2.  Primary:   Change on Hamilton Depression Rating Scale   [ Time Frame: 14 weeks ]

3.  Primary:   Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores   [ Time Frame: 14 weeks ]

4.  Secondary:   Percentage of Abstinent Days   [ Time Frame: over four weeks, from week 11 through 14 ]

5.  Secondary:   Change in Alcohol Urge Questionnaire Score   [ Time Frame: from baseline to endpoint, 14 weeks ]

6.  Secondary:   Change in Gamma Glutamyl Transferase (GGT)   [ Time Frame: 14 weeks ]

7.  Secondary:   Change in Beck Depression Inventory (BDI) Scores   [ Time Frame: 14 weeks ]

8.  Secondary:   Percentage of Total Drinking Days   [ Time Frame: 4 weeks ]

9.  Secondary:   Change in Number of Heavy Drinking Days Per Week by Time   [ Time Frame: 14 weeks (baseline to endpoint) ]

10.  Secondary:   Change in Number of Drinks Per Week by Time   [ Time Frame: 14 weeks (baseline to endpoint) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Albert Arias
Organization: Yale/VA Connecticut Healthcare system
phone: 2039325711 ext 8155
e-mail: albert.arias@va.gov



Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT01566370     History of Changes
Other Study ID Numbers: ZNS-BP
VACT MIRECC ( Other Identifier: VA )
K23AA017689 ( U.S. NIH Grant/Contract )
First Submitted: December 15, 2011
First Posted: March 29, 2012
Results First Submitted: March 22, 2016
Results First Posted: April 22, 2016
Last Update Posted: January 13, 2017